<DOC>
	<DOCNO>NCT01687270</DOCNO>
	<brief_summary>This open-label , single-arm study sofosbuvir ( GS-7977 ) ribavirin ( RBV ) adult liver transplant become re-infected hepatitis C. The treatment period 24 week 48 week follow . The total time study last 72 week include screen visit .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir Ribavirin Adults With Recurrent Chronic Hepatitis C Virus ( HCV ) Post Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Subjects evidence chronic HCV ( genotype ) document pretransplantation HCV RNA ≥ 10,000 IU/mL screen Absence organ rejection document post transplant liver biopsy take 12 month prior baseline/Day 1 visit Liver transplant ≥ 6 month ≤ 12 year prior screen Naive nucleotide/nucleoside treatment chronic HCV infection Multiorgan transplant include heart lung recipient Subjects de novo recurrent Hepatocellular Carcinoma ( HCC ) post transplant Current use corticosteroid dose &gt; 5mg prednisone/day ( equivalent dose corticosteroid ) Infection hepatitis B virus ( HBV ) HIV screen Current , uncontrolled ascites , variceal hemorrhage , hepatic encephalopathy , hepatorenal syndrome , hepatopulmonary syndrome , sign decompensated cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>